Literature DB >> 18216146

Acid, basic, and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma.

Lorena Blanco1, Gorka Larrinaga, Itxaro Pérez, José I López, Javier Gil, Ekaitz Agirregoitia, Adolfo Varona.   

Abstract

Renal cell carcinomas (RCCs) are neoplasias with high prevalence and mortality. We previously reported that several peptidases may be involved in the pathophysiology of clear cell renal cell carcinoma (CCRCC). Now, to gain insight into the reasons that lead the various RCC types to behave very differently with regard to aggressiveness and response to anticancer treatments, we analyzed subsets of chromophobe renal cell carcinoma (ChRCC), and renal oncocytoma (RO), a benign tumor; as well as different grades and stages of CCRCCs. Particulate APN, APB, and APA activities were decreased in both ChRCC and RO (tumor vs. nontumor tissues). Interestingly, activities were downregulated in a tumor-type specific way and the intensities of the decreases were stronger in the benign tumor than in the malignant type. Moreover, when two key histopathological parameters for tumor prognosis (high vs. low stage and grade) were analyzed, increases of activity were also observed in several of these cell surface peptidases (APN, APB). Some soluble activities (APB, Asp-AP) were also downregulated in the RCCs. With respect to genetic expression, PSA and APN were in a positive correlation related to their activities in both ChRCC and RO; but not APB, Asp-AP, APA, and PGI. These results may suggest an involvement of several peptidases in the pathophysiology of renal cancer, since they presented different patterns of activity and expression in tumors with different behaviors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18216146     DOI: 10.1152/ajprenal.00469.2007

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  5 in total

1.  Cannabinoid CB₁ receptor is downregulated in clear cell renal cell carcinoma.

Authors:  Gorka Larrinaga; Begoña Sanz; Itxaro Pérez; Lorena Blanco; María L Cándenas; Francisco M Pinto; Javier Gil; José I López
Journal:  J Histochem Cytochem       Date:  2010-09-17       Impact factor: 2.479

2.  Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.

Authors:  Adolfo Varona; Lorena Blanco; Itxaro Perez; Javier Gil; Jon Irazusta; José I López; M Luz Candenas; Francisco M Pinto; Gorka Larrinaga
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

3.  Altered Activity and Expression of Cytosolic Peptidases in Colorectal Cancer.

Authors:  Itxaro Perez; Lorena Blanco; Begoña Sanz; Peio Errarte; Usue Ariz; Maider Beitia; Ainhoa Fernández; Alberto Loizate; M Luz Candenas; Francisco M Pinto; Javier Gil; José I López; Gorka Larrinaga
Journal:  Int J Med Sci       Date:  2015-06-02       Impact factor: 3.738

4.  Altered peptidase activities in thyroid neoplasia and hyperplasia.

Authors:  Gorka Larrinaga; Lorena Blanco; Peio Errarte; Maider Beitia; Begoña Sanz; Itxaro Perez; Amaia Irazusta; Clara E Sánchez; Francisco Santaolalla; Leire Andrés; José I López
Journal:  Dis Markers       Date:  2013-11-27       Impact factor: 3.434

5.  Altered glutamyl-aminopeptidase activity and expression in renal neoplasms.

Authors:  Lorena Blanco; Begoña Sanz; Itxaro Perez; Clara E Sánchez; M Luz Cándenas; Francisco M Pinto; Javier Gil; Luis Casis; José I López; Gorka Larrinaga
Journal:  BMC Cancer       Date:  2014-05-30       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.